ETFs with VICL as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.85%||PowerShares Lux Nanotech Portfolio (PXN)||+0.08 (1.30%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We research and develop biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. We believe the following areas of research offer the greatest potential for near-term commercialization for us and our partners: • Vaccines for use in high-risk populations for infectious disease targets for which there are significant needs; • Vaccines for general pediatric, adolescent and adult populations for infectious disease applications; • Cancer vaccines or immunotherapies that complement our existing programs and core expertise; and • Gene-based delivery of therapeutic proteins, such as angiogenic growth factors for treatment of cardiovascular diseases. ... More ...